Inhibition of human and rat CYP1A1 enzyme by grapefruit juice compounds

被引:17
|
作者
Santes-Palacios, Rebeca [1 ]
Romo-Mancillas, Antonio [2 ]
Camacho-Carranza, Rafael [1 ]
Javier Espinosa-Aguirre, Jesus [1 ]
机构
[1] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Med Genom & Toxicol Ambiental, Ap Postal 70-228, Mexico City 04510, DF, Mexico
[2] Univ Autonoma Queretaro, Fac Quim, Div Estudios Posgrad, Santiago De Queretaro, Mexico
关键词
Naringenin; Dihydroxybergamottin; CYP1A1; inhibitor; Molecular modeling; CYTOCHROMES P450 1A1; IN-VITRO INHIBITION; PARTICLE MESH EWALD; SUBSTRATE-BINDING; HUMAN-LIVER; SIMVASTATIN METABOLISM; MOLECULAR-DYNAMICS; O-DEETHYLATION; HOMOLOGY; DERIVATIVES;
D O I
10.1016/j.toxlet.2016.07.023
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Cytochrome P4501A1 is involved in the metabolism of carcinogenic polycyclic aromatic hydrocarbons; therefore, its inhibition interferes with the carcinogenesis process induced by these compounds in rats. The human and rat CYP1A1 differ by 21% in amino acid sequence, including the active site of the enzyme; this difference may be an important factor when results obtained using animal models are interpolated to humans. Based on its previously reported CYP inhibitory properties, we studied the effects of two molecules contained within grapefruit juice, naringenin and 6',7'-dihydroxybergamottin, on human and rat CYP1A1 activity. For this purpose, the kinetics of inhibition as well as computational simulations were used. Naringenin and 60,70-dihydroxybergamottin were found to be competitive inhibitors of human and rat CYP1A1. Additionally, naringenin exerted a mixed type inhibition effect on rat CYP1A1. Computational docking showed that inhibitors might block the oxidation of 7-ethoxyresorufin by binding to the CYP1A1 active site. Our results demonstrate the differences in CYP inhibitory mechanisms for the same molecule when CYP from different species are considered. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:267 / 275
页数:9
相关论文
共 50 条
  • [21] CYP1A2 is expressed along with CYP1A1 in the human lung
    Wei, C
    Cacavale, RJ
    Kehoe, JJ
    Thomas, PE
    Iba, MM
    CANCER LETTERS, 2001, 164 (01) : 25 - 32
  • [22] Arsenite inhibition of TCDD inducible human CYP1A1 transcription is independent of the Ah receptor
    Bonzo, JA
    Chen, SJ
    Tukey, RH
    FASEB JOURNAL, 2005, 19 (05): : A1566 - A1566
  • [23] EXPRESSION OF CYP1A1 AND CYP1A2 GENES IN HUMAN LIVER
    SCHWEIKL, H
    TAYLOR, JA
    KITAREEWAN, S
    LINKO, P
    NAGORNEY, D
    GOLDSTEIN, JA
    PHARMACOGENETICS, 1993, 3 (05): : 239 - 249
  • [24] CYP1A1 but not CYP1A2 proteins are expressed in human lymphocytes
    Spatzenegger, M
    Horsmans, Y
    Verbeeck, RK
    PHARMACOLOGY & TOXICOLOGY, 2000, 86 (05): : 242 - 244
  • [25] Insecticide cytotoxicity and CYP1A1/2 induction in primary human and rat hepatocyte cultures
    deSousa, G
    Fontaine, F
    Pralavorio, M
    BottaFridlund, D
    Letreut, Y
    Rahmani, R
    TOXICOLOGY IN VITRO, 1997, 11 (05) : 451 - &
  • [26] The effect of synthetic glucocorticoid, dexamethasone on CYP1A1 inducibility in adult rat and human hepatocytes
    Monostory, K
    Kohalmy, K
    Prough, RA
    Kóbori, L
    Vereczkey, L
    FEBS LETTERS, 2005, 579 (01): : 229 - 235
  • [27] Inhibition of CYP1A1 Alleviates Colchicine-Induced Hepatotoxicity
    Huang, Ruoyue
    Duan, Jingyi
    Huang, Wen
    Cheng, Yan
    Zhu, Beiwei
    Li, Fei
    TOXINS, 2024, 16 (01)
  • [28] Inhibition of CYP1A1 in vitro by berries with different quercetin contents
    Kansanen, L
    Mykkänen, H
    Törrönen, R
    NATURAL ANTIOXIDANTS AND ANTICARCINOGENS IN NUTRITION, HEALTH AND DISEASE, 1999, (240): : 395 - 397
  • [29] Effects of CYP1A1, AHR, and GSTM1 genetic polymorphisms and smoking status on human pulmonary CYP1A1 activities
    Smith, GBJ
    Harper, PA
    Wong, JMY
    Lam, MSM
    Reid, KR
    Petsikas, D
    Massey, TE
    TOXICOLOGY, 2001, 164 (1-3) : 152 - 152
  • [30] Cell-specific regulation of human CYP1A1 and CYP1B1
    Kress, S
    Greenlee, WF
    CANCER RESEARCH, 1997, 57 (07) : 1264 - 1269